Challenge Your Exam Readiness With Our Free ADC Practice Questions

Opioid tolerance is primarily driven by neuroadaptations at mu-opioid receptors, including receptor desensitization and downregulation. With repeated exposure, G-protein coupled receptor signaling becomes less responsive, necessitating higher opioid doses to achieve the same analgesic or euphorigenic effect. While pharmacokinetic factors (Option B) can contribute—such as enzyme induction for some substances—opioids are not classically associated with major hepatic enzyme induction explaining rapid tolerance. Cross-sensitization (Option A) refers to enhanced responsiveness to a drug following repeated exposure to another, and while dopaminergic pathways are implicated in reward, cross-sensitization is not the central mechanism of escalating therapeutic opioid dose. Kindling (Option D) involves progressive neuronal sensitization typically described in withdrawal or seizure contexts (e.g., alcohol/benzodiazepines) rather than explaining opioid dose escalation in ongoing use. Understanding receptor-level tolerance helps clinicians anticipate dependence, recognize overdose risk when tolerance fluctuates (e.g., after abstinence), and plan safer prescribing and tapering. It also underscores the importance of multimodal pain management, non-opioid alternatives, and close monitoring to prevent iatrogenic progression from therapeutic use to misuse.